PMC7186846_01
Representative computed tomography (CT) obtained throughout the clinical course. (A-C) CT during initial therapy (prior to the first time of pembrolizumab administration). (D-F) Progressive disease while receiving pembrolizumab therapy. (G-I) Significant reduction in tumor burden following the fourth dose of pembrolizumab after re-administration.
fonc-10-00507-g0001.jpg
PMC7186846_01_fonc-10-00507-g0001.jpg
F1
Two months following this, the nodules enlarged according to CT (Figures 1A-C). The efficacy evaluation was immune progressive disease in February 2019 and confirmed progressive disease in April 2019 (Figures 1D-F). PR was observed (Figures 1G-I). Pembrolizumab was tolerated well, and grade one fatigue and grade one hypothyroidism occurred during the treatment.